ITP
MCID: THR001
MIFTS: 61

Thrombocytopenia Due to Platelet Alloimmunization (ITP)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Thrombocytopenia Due to Platelet Alloimmunization

MalaCards integrated aliases for Thrombocytopenia Due to Platelet Alloimmunization:

Name: Thrombocytopenia Due to Platelet Alloimmunization 11 14 71
Immune Thrombocytopenia 11 19 42 58 75 14 63
Autoimmune Thrombocytopenia 42 58 28 53 5 71
Immune Thrombocytopenic Purpura 42 58 71
Itp 42 58
Thrombocytopenia Due to Immune Destruction 11
Idiopathic Thrombocytopenic Purpura 42
Autoimmune Thrombocytopenic Purpura 42
Auto-Immune Thrombocytopenia 11
Werlhof Disease 42

Characteristics:


Prevelance:

Immune Thrombocytopenia: 1-5/10000 (Europe, Denmark) 1-9/100000 (United States, United Kingdom, Denmark, France) 58

Age Of Onset:

Immune Thrombocytopenia: All ages 58

Age Of Death:

Immune Thrombocytopenia: any age 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:1587
NCIt 49 C3991
SNOMED-CT 68 2897005
MESH via Orphanet 44 D016553
ICD10 via Orphanet 32 D69.3
UMLS via Orphanet 72 C0242584 C0398650
UMLS 71 C0242584 C0272286 C0398650

Summaries for Thrombocytopenia Due to Platelet Alloimmunization

MedlinePlus Genetics: 42 Immune thrombocytopenia is a disorder characterized by a blood abnormality called thrombocytopenia, which is a shortage of blood cells called platelets that are needed for normal blood clotting.Affected individuals can develop red or purple spots on the skin caused by bleeding just under the skin's surface. Small spots of bleeding under the skin are called purpura and larger spots are called ecchymoses. People with immune thrombocytopenia can have significant bleeding episodes, such as nose bleeds (epistaxis) or bleeding in the moist lining (mucosae) of the mouth. In severe cases, individuals may have gastrointestinal bleeding or blood in the urine or stool, or heavy and prolonged menstrual bleeding (menorrhagia). In very rare instances, bleeding inside the skull (intracranial hemorrhage) can occur, which can be life-threatening. A greater reduction in platelet numbers is often associated with more frequent bleeding episodes and an increased risk of severe bleeding.While immune thrombocytopenia can be diagnosed at any age, there are two periods when the condition is most likely to develop: early childhood and late adulthood. In children, the reduction in platelets is often sudden, but platelet levels usually return to normal levels within weeks to months. Immune thrombocytopenia in children is often preceded by a minor infection, such as an upper respiratory infection, but the relationship between the infection and immune thrombocytopenia is not clear. In adults, the development of immune thrombocytopenia is usually gradual and the condition tends to persist throughout life.

MalaCards based summary: Thrombocytopenia Due to Platelet Alloimmunization, also known as immune thrombocytopenia, is related to purpura and splenic marginal zone lymphoma. An important gene associated with Thrombocytopenia Due to Platelet Alloimmunization is FCGR2C (Fc Gamma Receptor IIc (Gene/Pseudogene)), and among its related pathways/superpathways are Akt Signaling and Response to elevated platelet cytosolic Ca2+. The drugs Prednisolone phosphate and Prednisolone acetate have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and skin, and related phenotypes are thrombocytopenia and thromboembolism

PubMed Health : 63 Immune thrombocytopenia: Immune thrombocytopenia (THROM-bo-si-toe-PE-ne-ah), or ITP, is a bleeding disorder. In ITP, the blood doesn't clot as it should. This is due to a low number of blood cell fragments called platelets (PLATE-lets) or thrombocytes (THROM-bo-sites). Platelets are made in your bone marrow along with other kinds of blood cells. They stick together (clot) to seal small cuts or breaks on blood vessel walls and stop bleeding.

Orphanet: 58 A rare autoimmune coagulation disorder characterized by isolated thrombocytopenia (a platelet count <100,000/microL), in the absence of any underlying disorder that may be associated with thrombocytopenia.

Wikipedia: 75 Immune thrombocytopenic purpura (ITP), also known as idiopathic thrombocytopenic purpura or immune... more...

Related Diseases for Thrombocytopenia Due to Platelet Alloimmunization

Diseases in the Thrombocytopenia family:

Thrombocytopenia 2 Thrombocytopenia 3
Thrombocytopenia 1 Thrombocytopenia 4
Thrombocytopenia 5 Thrombocytopenia 6
Thrombocytopenia 7 Acquired Thrombocytopenia
Thrombocytopenia Due to Platelet Alloimmunization Primary Thrombocytopenia
Ankrd26-Related Thrombocytopenia

Diseases related to Thrombocytopenia Due to Platelet Alloimmunization via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1354)
# Related Disease Score Top Affiliating Genes
1 purpura 32.2 THPO SELP PF4 MPL ITGB3 ITGA2B
2 splenic marginal zone lymphoma 31.9 U2AF1 CD19 CCR6
3 evans' syndrome 31.9 U2AF1 THPO MPL CD8A CD4 CD19
4 thrombocytopenic purpura, autoimmune 31.4 THPO SOCS1 SELP PF4 MPL ITGB3
5 antiphospholipid syndrome 31.1 SELP PF4 GP1BA
6 acquired thrombocytopenia 31.1 THPO MPL ITGB3 ITGA2B GP1BA
7 hemorrhagic disease 31.0 THPO PF4 ITGA2B GP1BA
8 thrombocytosis 31.0 U2AF1 THPO SELP PF4 MPL
9 colitis 30.9 SYK SOCS1 ICOSLG CD4 CCR6
10 human cytomegalovirus infection 30.9 CD8A CD4 CCR6
11 henoch-schoenlein purpura 30.9 ICOSLG CD4 CCR6
12 chickenpox 30.9 CD8A CD4 CD19 CCR6
13 dengue disease 30.9 CD8A CD4 CCR6
14 qualitative platelet defect 30.9 THPO SELP ITGA2B GP1BA
15 thrombocytopenia 30.9 U2AF1 THPO SYK SOCS1 SELP PF4
16 crohn's disease 30.9 ICOSLG CD8A CD4 CCR6
17 infective endocarditis 30.8 ITGA2B GP1BA CCR6
18 exanthem 30.8 ICOSLG CD8A CD4 CD19 CCR6
19 autoimmune polyendocrine syndrome 30.8 ICOSLG CD4 CCR6
20 pernicious anemia 30.8 ICOSLG CD4 CCR6
21 immune deficiency disease 30.8 SYK ICOSLG FCGR2A CD8A CD4 CCR6
22 severe cutaneous adverse reaction 30.8 CD8A CD4 CCR6
23 thrombosis 30.8 SELP PF4 MPL ITGB3 ITGA2B GP1BA
24 anemia, autoimmune hemolytic 30.8 SOCS1 ICOSLG CD8A CD4 CD19 CCR6
25 portal vein thrombosis 30.7 THPO PF4 MPL
26 thrombasthenia 30.7 SELP ITGB3 ITGA2B GP1BA
27 hemoglobinuria 30.7 THPO SELP MPL
28 heparin-induced thrombocytopenia 30.7 PF4 ITGB3 ITGA2B FCGR2A
29 von willebrand's disease 30.7 SELP ITGA2B GP1BA
30 myelofibrosis 30.7 U2AF1 THPO SELP MPL
31 celiac disease 1 30.6 ICOSLG CD8A CD4 CD19 CCR6
32 hypersplenism 30.6 U2AF1 THPO CD4
33 orchitis 30.6 CD8A CD4 CCR6
34 agammaglobulinemia, x-linked 30.6 SYK ICOSLG CD19 CCR6
35 glanzmann thrombasthenia 1 30.6 SELP PF4 ITGB3 ITGA2B GP1BA
36 poliomyelitis 30.6 FCGR2A CD8A CD4
37 proliferative glomerulonephritis 30.5 SELP ICOSLG CCR6
38 primary biliary cholangitis 30.5 ICOSLG CD8A CD4 CCR6
39 igg4-related disease 30.5 ICOSLG CD4 CD19 CCR6
40 sclerosing cholangitis 30.5 ICOSLG CD8A CD4 CCR6
41 myelitis 30.5 ITGB3 ITGA2B CCR6
42 hematologic cancer 30.5 U2AF1 THPO SYK MPL ICOSLG CCR6
43 fetal and neonatal alloimmune thrombocytopenia 30.5 ITGB3 ITGA2B GP1BA
44 herpes zoster 30.5 FCGR2A CD8A CD4 CCR6
45 diffuse large b-cell lymphoma 30.5 U2AF1 ICOSLG CD19 CCR6
46 cholangitis, primary sclerosing 30.5 ICOSLG CD8A CD4 CCR6
47 autoimmune pancreatitis 30.5 ICOSLG CD4 CCR6
48 childhood type dermatomyositis 30.5 ICOSLG CD4 CCR6
49 hypersensitivity vasculitis 30.5 ICOSLG CD4 CCR6
50 aplastic anemia 30.4 U2AF1 THPO MPL GP1BA CD8A CD4

Graphical network of the top 20 diseases related to Thrombocytopenia Due to Platelet Alloimmunization:



Diseases related to Thrombocytopenia Due to Platelet Alloimmunization

Symptoms & Phenotypes for Thrombocytopenia Due to Platelet Alloimmunization

Human phenotypes related to Thrombocytopenia Due to Platelet Alloimmunization:

58 30 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 thrombocytopenia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001873
2 thromboembolism 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001907
3 petechiae 58 30 Frequent (33%) Frequent (79-30%)
HP:0000967
4 arterial thrombosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0004420
5 gastrointestinal hemorrhage 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002239
6 epistaxis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000421
7 gingival bleeding 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000225
8 bruising susceptibility 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000978
9 cerebral hemorrhage 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001342
10 purpura 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Thrombocytopenia Due to Platelet Alloimmunization:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 CCR6 CD19 CD4 FCGR2A FCGR2C FCGRT
2 cellular MP:0005384 9.93 CD19 CD4 CD8A FCGR2A FCGR2C GP1BA
3 renal/urinary system MP:0005367 9.92 CD19 CD8A FCGR2A FCGR2C ITGB3 SELP
4 immune system MP:0005387 9.86 CCR6 CD19 CD4 CD8A FCGR2A FCGR2C
5 hematopoietic system MP:0005397 9.58 CCR6 CD19 CD4 CD8A FCGR2A FCGR2C

Drugs & Therapeutics for Thrombocytopenia Due to Platelet Alloimmunization

PubMed Health treatment related to Thrombocytopenia Due to Platelet Alloimmunization: 63

Treatment for immune thrombocytopenia (ITP) is based on how much and how often you're bleeding and your platelet count. Adults who have mild ITP may not need any treatment , other than watching their symptoms and platelet counts. Adults who have ITP with very low platelet counts or bleeding problems often are treated. The acute (short-term) type of ITP that occurs in children often goes away within a few weeks or months. Children who have bleeding symptoms, other than merely bruising (purpura ), usually are treated. Children who have mild ITP may not need treatment other than monitoring and followup to make sure their platelet counts return to normal.

Drugs for Thrombocytopenia Due to Platelet Alloimmunization (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 181)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
2
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
4
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
6
Hydroxychloroquine Approved Phase 4 118-42-3 3652
7
Clarithromycin Approved Phase 4 81103-11-9 84029
8
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
9
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6 9578005
10
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
11
Morphine Approved, Investigational Phase 4 57-27-2 5288826
12
Alemtuzumab Approved, Investigational Phase 4 216503-57-0
13
Glycyrrhizic acid Approved, Experimental Phase 4 1405-86-3 3495 14982
14
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453
15
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
16
3,4-Dihydroxycinnamic Acid Experimental, Investigational Phase 4 331-39-5, 501-16-6, 4361-87-9 689043 1549111
17
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
18
Enoxolone Investigational Phase 4 471-53-4 3230 18526330 10114
19 Calcium, Dietary Phase 4
20 Micronutrients Phase 4
21 Calciferol Phase 4
22 Vitamins Phase 4
23 Trace Elements Phase 4
24 Vasoconstrictor Agents Phase 4
25 Tin Fluorides Phase 4
26 Anti-Infective Agents Phase 4
27 Protective Agents Phase 4
28 Antimetabolites Phase 4
29 Antimalarials Phase 4
30 Antiprotozoal Agents Phase 4
31 Antiparasitic Agents Phase 4
32
Methylprednisolone Acetate Phase 4 584547
33 Neuroprotective Agents Phase 4
34 Proton Pump Inhibitors Phase 4
35 Cytochrome P-450 Enzyme Inhibitors Phase 4
36 Cytochrome P-450 CYP3A Inhibitors Phase 4
37 Tubulin Modulators Phase 4
38 Antimitotic Agents Phase 4
39 Anti-Ulcer Agents Phase 4
40 Antacids Phase 4
41
Calcium Nutraceutical Phase 4 7440-70-2 271
42
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
43
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
44
Dapsone Approved, Investigational Phase 3 80-08-0 2955
45
Pantoprazole Approved Phase 3 102625-70-7, 138786-67-1 4679
46
Selenium Approved, Investigational, Vet_approved Phase 2, Phase 3 7783-07-5, 7782-49-2 533
47
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 3640 5754
48
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
49
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
50
Acetaminophen Approved Phase 3 103-90-2 1983

Interventional clinical trials:

(show top 50) (show all 347)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Unknown status NCT03771378 Phase 4 rhTPO;eltrombopag
2 A Multicenter Randomized Open-label Clinical Trial of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP Unknown status NCT04094805 Phase 4 Rocaltrol;Dexamethasone
3 Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia in Pediatrics Unknown status NCT04102033 Phase 4 Eltrombopag
4 Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura Unknown status NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
5 A Multicenter, Randomized, Open-label Study To Compare The Efficacy And Safety Of Eltrombopag Combining Rituximab With Eltrombopag In Adult ITP Patients Unknown status NCT04518475 Phase 4 eltrombopag combining rituximab;eltrombopag
6 Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in Immune Thrombocytopenia: a Prospective Multicenter Open Study Unknown status NCT03119974 Phase 4 Tpo-RA discontinuation
7 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Completed NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
8 Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim Completed NCT02760251 Phase 4 romiplostim
9 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
10 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab
11 Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) Completed NCT04089267 Phase 4 TPO
12 An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis Completed NCT01390649 Phase 4
13 Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment Completed NCT03784898 Phase 4
14 A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
15 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
16 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
17 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
18 Efficacy and Safety of Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to Eltrombopag or Herombopag Treatment: a Single-center, Prospective, One-arm Clinical Trial Recruiting NCT04993885 Phase 4 Avatrombopag
19 Efficacy and Safety of Eltrombopag Combined With Low-dose Rituximab in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to First-line Treatment: a Prospective, Open-label, Nonrandomized, Multicenter Clinical Trial Recruiting NCT04915482 Phase 4 Combined use of eltrombopag with low-dose rituximab;The best available therapy
20 Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Recruiting NCT03866798 Phase 4
21 Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim Recruiting NCT04638829 Phase 4 Avatrombopag Oral Tablet
22 A Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03998982 Phase 4 Glycyrrhetinic Acid;Dexamethasone
23 A Multicenter, Randomized Controlled Study of Two Regimens of Intravenous Immune Globulin in the Treatment of Newly Diagnosed Immune Thrombocytopenia in Children Recruiting NCT05520892 Phase 4 intravenous immunoglobulin
24 Short-course High-dose Prednisone and Dexamethasone in Children With Immune A Multicenter, Randomized Controlled Study of Thrombocytopenia Recruiting NCT05522465 Phase 4 Prednisone;Dexamethasone
25 A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency) Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
26 Efficacy and Safety of TPO Receptor Agonists as First-line Drugs in the Treatment of Newly Diagnosed Elderly ITP Patients in China-an Open Label Study Not yet recruiting NCT05311930 Phase 4 2.5mg/d Hetrombopag
27 Comparing the Efficacy and Safety of Optimized rhTPO Treatment Versus Eltrombopag Treatment in Previously Treated Primary Immune Thrombocytopenia Patients: A Multicenter Randomized Open-label Trial Not yet recruiting NCT05583838 Phase 4 rhTPO;Eltrombopag
28 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
29 A Multicenter Clinical Study of Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia Unknown status NCT03492515 Phase 3 recombinant human thrombopoietin;Platelet Concentrate
30 Proof of Concept; A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia Unknown status NCT03520049 Phase 3 Oseltamivir;Placebo
31 A Multicenter Prospective Randomized Study of Rituximab Combined With Bortezomib Versus Rituximab in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Unknown status NCT03443570 Phase 3 Rituximab;Bortezomib
32 Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Unknown status NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
33 A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
34 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
35 A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia Unknown status NCT01805648 Phase 3 rhTPO
36 Efficacy of Helicobacter Pylori Eradication for the Treatment of Chronic or Persistent Immune Thrombocytopenic Purpura Patients With Moderate Thrombocytopenia: Multicenter Prospective Randomized Phase 3 Study Unknown status NCT03177629 Phase 3 treatment : H. pylori eradication
37 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial Unknown status NCT02270801 Phase 3 rhTPO
38 Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
39 A Multicenter Prospective Randomized Study of Dexamethasone Combined With Decitabine Versus Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Unknown status NCT03252457 Phase 3 Decitabine;Dexamethasone
40 A Multicentre Randomised Trial of First Line Treatment Pathways for Newly Diagnosed Immune Thrombocytopenia: Standard Steroid Treatment Versus Combined Steroid and Mycophenolate Unknown status NCT03156452 Phase 3 Mycophenolate Mofetil;Prednisolone
41 Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes Unknown status NCT02877212 Phase 3 Eltrombopag
42 Prospective, Non-Randomized, Open-label, Single-arm, Multi-Center Phase III Clinical Trial to Evaluate the Efficacy and Safety of IV-Globulin SN Inj.10% in the Patients Diagnosed With Immune Thrombocytopenia (ITP). Completed NCT02063789 Phase 3 Human immunoglobulin intravenous
43 A Randomized Study to Evaluate the Efficacy and Safety of Different Doses and Frequencies of Recombinant Human Thrombopoietin (rhTPO) in the Management of Primary Immune Thrombocytopenia (ITP) Completed NCT02139501 Phase 3 Recombinant Human Thrombopoietin (rhTPO)
44 An Open Label, Prospective, Randomized, Multicenter Study Investigating Clinical Efficacy and Safety of the Human Normal Immunoglobulin for Intravenous Administration BT595 in Patients With Chronic Primary Immune Thrombocytopenia (ITP) Completed NCT02859909 Phase 3
45 Rituximab as Second Line Treatment for ITP; A Multicenter, Randomized, Double Blind, Placebo-controlled, Phase III Study. "The RITP Study" Completed NCT00344149 Phase 3 Rituximab (Mabthera)
46 A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia (ITP) Completed NCT04188379 Phase 3
47 A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP) Completed NCT01444417 Phase 3 Romiplostim;Placebo
48 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenia Purpura) Completed NCT01438840 Phase 3 Avatrombopag;Placebo;Standard of care
49 A Multi-center, Randomized, Placebo-controlled, Double-blinded Then Open 2 Stages Clinical Trial to Evaluate the Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) Completed NCT02868099 Phase 3 Romiplostim;Placebo
50 A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP) Completed NCT03164915 Phase 3

Search NIH Clinical Center for Thrombocytopenia Due to Platelet Alloimmunization

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Azathioprine
Cyclophosphamide
Immunoglobulins, Intravenous
Intramuscular immunoglobulin
Rho(D) Immune Globulin, human
Venoglobulin-I
Vinblastine
Vinblastine Sulfate

Genetic Tests for Thrombocytopenia Due to Platelet Alloimmunization

Genetic tests related to Thrombocytopenia Due to Platelet Alloimmunization:

# Genetic test Affiliating Genes
1 Autoimmune Thrombocytopenia 28

Anatomical Context for Thrombocytopenia Due to Platelet Alloimmunization

Organs/tissues related to Thrombocytopenia Due to Platelet Alloimmunization:

MalaCards : Bone Marrow, Bone, Skin, T Cells, Spleen, B Cells, Nk Cells

Publications for Thrombocytopenia Due to Platelet Alloimmunization

Articles related to Thrombocytopenia Due to Platelet Alloimmunization:

(show top 50) (show all 11773)
# Title Authors PMID Year
1
[Autoimmune thrombocytopenia, neutropenia and hemolysis]. 53 62
19225748 2009
2
Flow cytometric evaluation of platelet activation in chronic autoimmune thrombocytopenia. 53 62
16933254 2006
3
Gene frequencies of the human platelet antigen-3 in different populations. 53 62
15678278 2005
4
Combined thrombopoietin and platelet response to altitude in a patient with autoimmune thrombocytopenia. 53 62
15025089 2004
5
The diagnostic value of thrombopoietin level measurements in thrombocytopenia. 53 62
9657431 1998
6
Varicella-associated thrombocytopenia: autoantibodies against platelet surface glycoprotein V. 53 62
8888292 1996
7
[The effect of blood from patients with idiopathic thrombocytopenia and thrombopoietin on the thrombocyte count in the blood of mice]. 53 62
8657073 1995
8
Clinical efficacy of recombinant human thrombopoietin combined with glucocorticoids in the treatment of immune thrombocytopenia. 62
36094428 2022
9
Investigation of the mechanism of action of Shengxuexiaoban Capsules against primary immune thrombocytopenia using network pharmacology and experimental validation. 62
36037773 2022
10
B cell-activating factor is involved in thrombocytopenia in patients with liver cirrhosis. 62
36098792 2022
11
Safety, tolerance, pharmacokinetic and pharmacodynamic properties of thrombopoietin mimetic peptide for injection in Chinese healthy volunteers: a randomized, placebo-controlled, double-blind study. 62
35549802 2022
12
Association between megakaryocyte abnormalities on bone marrow smear and response to thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia. 62
35348426 2022
13
Changing profile of platelet activity and turnover indices during treatment response of immune thrombocytopenia. 62
35137341 2022
14
Efficacy and steroid-sparing effect of tacrolimus in patients with autoimmune cytopenia. 62
36066607 2022
15
Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection. 62
36182877 2022
16
Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure. 62
35791514 2022
17
[Guillain-Barre syndrome and thrombocytopenia after SARS-CoV-2 vaccination with Moderna. A case report]. 62
36218255 2022
18
Splenectomy for wandering splenomegaly in a patient with idiopathic thrombocytopenic purpura: A case report of a rare association. 62
36261950 2022
19
Splenectomy outcomes in patients with autoimmune cytopenias and persistent antiphospholipid antibodies. 62
36208143 2022
20
Risk factors and characteristics of ischemic stroke in patients with immune thrombocytopenia: A retrospective cohort study. 62
36054971 2022
21
Chronic immune thrombocytopenia in a child with X-linked agammaglobulinemia-an uncommon phenotype. 62
35296220 2022
22
CT-514 Acute Cardiac Tamponade Following Adult Allogeneic Hematopoietic Transplantation. 62
36164223 2022
23
Immune thrombocytopenia and risk of stroke: Evidence from a nationwide population-based cohort study. 62
36073612 2022
24
TNF-alpha releasing capacity of the whole blood drops after open total splenectomy, but increases after partial/subtotal or minimally invasive splenectomy. 62
33886417 2022
25
[Factors Influencing the efficacy of Plasma Exchange in the Treatment of Immune Thrombocytopenic Purpura]. 62
36208267 2022
26
Vaccine-Induced Immune Thrombocytopenia and Thrombosis after the Sputnik V Vaccine. 62
36103622 2022
27
Deciphering transcriptome alterations in bone marrow hematopoiesis at single-cell resolution in immune thrombocytopenia. 62
36202780 2022
28
Enhancing regulatory T cell function via inhibition of high mobility group box 1 protein signaling in immune thrombocytopenia. 62
36263841 2022
29
Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen. 62
35870368 2022
30
High-throughput DNA methylation analysis in ITP confirms NOTCH1 hypermethylation through the Th1 and Th2 cell differentiation pathways. 62
35930913 2022
31
Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the FDA adverse event reporting system. 62
35644838 2022
32
HDAC3 single-nucleotide polymorphism rs2530223 is associated with increased susceptibility and severity of primary immune thrombocytopenia. 62
35484920 2022
33
Therapeutic plasma exchange practices in immune thrombocytopenia related hospitalizations: Results from a nationally representative sample. 62
35979873 2022
34
Intramuscular Anti-D treatment for immune thrombocytopenia: A single centre experience. 62
36198407 2022
35
Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia. 62
36195695 2022
36
The short-term predictive value of CD4+ cells for combination therapy with high-dose dexamethasone and immunoglobulin in newly diagnosed primary immune thrombocytopenia patients. 62
36054980 2022
37
First-line Therapy for Immune Thrombocytopenia: Time for Change. 62
36168521 2022
38
Japanese and French translation and linguistic validation of a patient-reported outcome tool to assess quality of life in patients with Immune Thrombocytopenia (ITP): the ITP Life Quality Index (ILQI). 62
35675024 2022
39
Erratum for "Investigation of single-nucleotide polymorphisms in the NR3C1a glucocorticoid receptor gene in Cocker Spaniels with primary immune thrombocytopenia". 62
35962635 2022
40
COVID-19-Associated Immune Thrombocytopenia in a Toddler: Correspondence. 62
35701682 2022
41
A rare case of pediatric immune thrombocytopenia with secondary antiphospholipid syndrome in Korea. 62
35920092 2022
42
Safety and efficacy of splenectomy for the treatment of chronic immune thrombocytopenia. 62
36175771 2022
43
Dosing of intravenous immunoglobulin in COVID-19 vaccine-induced immune thrombocytopenia and thrombosis. 62
36175122 2022
44
Successful phytotherapy for a patient with severe immune thrombocytopenia and failed with corticosteroids, azathioprine, eltrombopag, and platelet transfusion - A case report. 62
35473821 2022
45
A Systematic Review of Reported Cases of Immune Thrombocytopenia after COVID-19 Vaccination. 62
36146522 2022
46
Development and internal validation of a clinical prediction model for the diagnosis of immune thrombocytopenia. 62
36121734 2022
47
Thrombopoietin receptor agonist discontinuation rates and reasons among patients with immune thrombocytopenia: a study of administrative claims linked with medical chart review. 62
35849155 2022
48
Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, Middle East, and Turkey: final analysis of CITE. 62
36103340 2022
49
A narrative review of anti-SARS-CoV-2 vaccines and immune thrombocytopenia: be aware, but reassured. 62
36125949 2022
50
Regulatory T cells are replenished in the splenic microenvironment of patients with immune thrombocytopenia by treatment with thrombopoietin receptor agonists. 62
35748239 2022

Variations for Thrombocytopenia Due to Platelet Alloimmunization

ClinVar genetic disease variations for Thrombocytopenia Due to Platelet Alloimmunization:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SOCS1 NM_003745.2(SOCS1):c.24del (p.Ala9fs) DEL Likely Pathogenic
977213 rs2069587477 GRCh37: 16:11349312-11349312
GRCh38: 16:11255455-11255455
2 SOCS1 NM_003745.2(SOCS1):c.476_480dup (p.Met161fs) MICROSAT Likely Pathogenic
977214 rs1470306246 GRCh37: 16:11348855-11348856
GRCh38: 16:11254998-11254999

Expression for Thrombocytopenia Due to Platelet Alloimmunization

Search GEO for disease gene expression data for Thrombocytopenia Due to Platelet Alloimmunization.

Pathways for Thrombocytopenia Due to Platelet Alloimmunization

Pathways related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 THPO SYK PF4 ITGB3 ITGA2B CD4
2
Show member pathways
12.97 THPO SYK SELP PF4 MPL ITGB3
3 12.28 SYK SOCS1 MPL CD8A CD19
4
Show member pathways
12.18 SYK ICOSLG CD8A CD4
5 11.59 CD8A CD4 CCR6
6 11.52 CD8A CD4 CD19
7
Show member pathways
11.48 THPO SYK MPL ITGB3 ITGA2B GP5
8 11.47 CD19 ICOSLG IFNG-AS1 SYK
9 11.41 SOCS1 SELP ITGB3
10 11.39 THPO MPL ITGB3 ITGA2B GP5 GP1BA
11 11.32 ITGB3 ITGA2B GP5
12 11.24 ITGB3 ITGA2B FCGR2A
13 11.12 PF4 ITGB3 ITGA2B FCGR2A CD4

GO Terms for Thrombocytopenia Due to Platelet Alloimmunization

Cellular components related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016021 10.4 CCR6 CD19 CD4 CD8A FCGR2A FCGRT
2 membrane GO:0016020 10.4 CCR6 CD19 CD4 CD8A FCGR2A FCGRT
3 plasma membrane GO:0005886 10.09 CCR6 CD19 CD4 CD8A FCGR2A GP1BA
4 plasma membrane GO:0005887 10.09 CCR6 CD19 CD4 CD8A FCGR2A GP1BA
5 external side of plasma membrane GO:0009897 9.64 SELP MPL ITGB3 ITGA2B ICOSLG GP1BA
6 platelet alpha granule membrane GO:0031092 9.63 SELP ITGB3 ITGA2B
7 glycoprotein Ib-IX-V complex GO:1990779 9.62 GP5 GP1BA

Biological processes related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10.06 PF4 FCGRT FCGR2C CD8A CD4 CCR6
2 platelet aggregation GO:0070527 9.91 MPL ITGB3 GP1BA
3 immune system process GO:0002376 9.87 SYK ICOSLG FCGR2A CD8A CD4 CD19
4 cell surface receptor signaling pathway GO:0007166 9.85 SYK GP1BA FCGR2C FCGR2A CD8A CD4
5 megakaryocyte development GO:0035855 9.73 GP1BA GP5 THPO
6 thrombopoietin-mediated signaling pathway GO:0038163 9.67 THPO MPL
7 platelet activation GO:0030168 9.56 SYK PF4 ITGB3 GP1BA
8 positive regulation of platelet activation GO:0010572 9.1 SELP GP5 GP1BA

Molecular functions related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 coreceptor activity GO:0015026 9.43 ITGB3 CD8A CD4
2 IgG binding GO:0019864 9.02 FCGRT FCGR2C FCGR2A

Sources for Thrombocytopenia Due to Platelet Alloimmunization

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....